Hoermann R, Midgley J E M, Larisch R, Dietrich J W
Department of Nuclear Medicine, Klinikum Luedenscheid, 58515 Luedenscheid, Germany.
North Lakes Clinical, Ilkley, UK.
Horm Metab Res. 2015 Aug;47(9):674-80. doi: 10.1055/s-0034-1398616. Epub 2015 Mar 6.
The objective of the study was to evaluate the roles of central and peripheral T3 regulation. In a prospective study involving 1,796 patients, the equilibria between FT3 and TSH were compared in untreated and L-T4-treated patients with varying functional states, residual thyroid secretory capacities and magnitudes of TSH stimulation. T3 concentrations were stable over wide variations in TSH levels (from 0.2 to 7 mU/l) and endogenous T4 production in untreated patients, but unbalanced in L-T4-treated athyreotic patients where T3 correlated with exogenous T4 supply. T3 stability was related to TSH-stimulated deiodinase activity by clinical observation, as predicted by theoretical modelling. Deiodinase activity in treated patients was reduced due to both diminished responsiveness to TSH and lack of thyroidal capacity. Deiodinase activity was increased in high thyroid volume, compared to lower volumes in euthyroid patients (<5 ml, p<0.001). While deiodinase differed between euthyroid and subclinically hypothyroid patients in high volume, 26.7 nmol/s (23.6, 29.2), n=214 vs. 28.9 nmol/s (26.7, 31.5), n=20, p=0.02, it was equivalent between the 2 functional groups in low volume, 23.3 nmol/s (21.3, 26.1), n=117 vs. 24.6 nmol/s (22.2, 27.5), n=38, p=0.22. These findings suggest that the thyroid gland and peripheral tissues are integrated in the physiological process of T3 homeostasis in humans via a feed-forward TSH motif, which coordinates peripheral and central regulatory mechanisms. Regulatory and capacity deficiencies collectively impair T3 homeostasis in L-T4-treated patients.
本研究的目的是评估中枢和外周T3调节的作用。在一项涉及1796例患者的前瞻性研究中,比较了不同功能状态、残余甲状腺分泌能力和TSH刺激程度的未治疗患者和L-T4治疗患者中FT3与TSH之间的平衡。在未治疗患者中,TSH水平(从0.2至7mU/l)和内源性T4产生有很大变化时,T3浓度保持稳定,但在L-T4治疗的甲状腺切除患者中则不平衡,其中T3与外源性T4供应相关。临床观察显示,T3稳定性与TSH刺激的脱碘酶活性有关,这与理论模型预测一致。治疗患者的脱碘酶活性降低,这是由于对TSH的反应性降低和甲状腺能力缺乏所致。与甲状腺体积较小的甲状腺功能正常患者相比,甲状腺体积较大患者的脱碘酶活性增加(<5ml,p<0.001)。虽然甲状腺体积较大的甲状腺功能正常患者和亚临床甲状腺功能减退患者的脱碘酶活性不同,分别为26.7nmol/s(23.6,29.2),n = 214和28.9nmol/s(26.7,31.5),n = 20,p = 0.02,但在甲状腺体积较小的情况下,这两个功能组之间的脱碘酶活性相当,分别为23.3nmol/s(21.3,26.1),n = 117和24.6nmol/s(22.2,27.5),n = 38,p = 0.22。这些发现表明,甲状腺和外周组织通过前馈TSH基序整合到人类T3稳态的生理过程中,该基序协调外周和中枢调节机制。调节和能力缺陷共同损害L-T4治疗患者的T3稳态。